406 related articles for article (PubMed ID: 22196945)
21. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
Brocklehurst P; Volmink J
Cochrane Database Syst Rev; 2002; (1):CD003510. PubMed ID: 11869666
[TBL] [Abstract][Full Text] [Related]
22. Twelve-month follow-up of Six Week Extended Dose Nevirapine randomized controlled trials: differential impact of extended-dose nevirapine on mother-to-child transmission and infant death by maternal CD4 cell count.
Omer SB;
AIDS; 2011 Mar; 25(6):767-76. PubMed ID: 21330912
[TBL] [Abstract][Full Text] [Related]
23. Prevention of HIV-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in HIV-1-Infected Women With High CD4 Cell Count (IMPAACT PROMISE): A Randomized, Open-Label, Clinical Trial.
Flynn PM; Taha TE; Cababasay M; Fowler MG; Mofenson LM; Owor M; Fiscus S; Stranix-Chibanda L; Coutsoudis A; Gnanashanmugam D; Chakhtoura N; McCarthy K; Mukuzunga C; Makanani B; Moodley D; Nematadzira T; Kusakara B; Patil S; Vhembo T; Bobat R; Mmbaga BT; Masenya M; Nyati M; Theron G; Mulenga H; Butler K; Shapiro DE;
J Acquir Immune Defic Syndr; 2018 Apr; 77(4):383-392. PubMed ID: 29239901
[TBL] [Abstract][Full Text] [Related]
24. Longitudinal adherence to maternal antiretroviral therapy and infant Nevirapine prophylaxis from 6 weeks to 18 months postpartum amongst a cohort of mothers and infants in South Africa.
Larsen A; Magasana V; Dinh TH; Ngandu N; Lombard C; Cheyip M; Ayalew K; Chirinda W; Kindra G; Jackson D; Goga A
BMC Infect Dis; 2019 Sep; 19(Suppl 1):789. PubMed ID: 31526366
[TBL] [Abstract][Full Text] [Related]
25. Response to antiretroviral therapy after a single, peripartum dose of nevirapine.
Lockman S; Shapiro RL; Smeaton LM; Wester C; Thior I; Stevens L; Chand F; Makhema J; Moffat C; Asmelash A; Ndase P; Arimi P; van Widenfelt E; Mazhani L; Novitsky V; Lagakos S; Essex M
N Engl J Med; 2007 Jan; 356(2):135-47. PubMed ID: 17215531
[TBL] [Abstract][Full Text] [Related]
26. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
Chasela CS; Hudgens MG; Jamieson DJ; Kayira D; Hosseinipour MC; Kourtis AP; Martinson F; Tegha G; Knight RJ; Ahmed YI; Kamwendo DD; Hoffman IF; Ellington SR; Kacheche Z; Soko A; Wiener JB; Fiscus SA; Kazembe P; Mofolo IA; Chigwenembe M; Sichali DS; van der Horst CM;
N Engl J Med; 2010 Jun; 362(24):2271-81. PubMed ID: 20554982
[TBL] [Abstract][Full Text] [Related]
27. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial.
Dorenbaum A; Cunningham CK; Gelber RD; Culnane M; Mofenson L; Britto P; Rekacewicz C; Newell ML; Delfraissy JF; Cunningham-Schrader B; Mirochnick M; Sullivan JL;
JAMA; 2002 Jul; 288(2):189-98. PubMed ID: 12095383
[TBL] [Abstract][Full Text] [Related]
28. A randomized, double-blind, placebo-controlled trial of combined nevirapine and zidovudine compared with nevirapine alone in the prevention of perinatal transmission of HIV in Zimbabwe.
Thistle P; Spitzer RF; Glazier RH; Pilon R; Arbess G; Simor A; Boyle E; Chitsike I; Chipato T; Gottesman M; Silverman M
Clin Infect Dis; 2007 Jan; 44(1):111-9. PubMed ID: 17143826
[TBL] [Abstract][Full Text] [Related]
29. Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial.
Taha TE; Kumwenda NI; Hoover DR; Fiscus SA; Kafulafula G; Nkhoma C; Nour S; Chen S; Liomba G; Miotti PG; Broadhead RL
JAMA; 2004 Jul; 292(2):202-9. PubMed ID: 15249569
[TBL] [Abstract][Full Text] [Related]
30. Lopinavir/Ritonavir versus Lamivudine peri-exposure prophylaxis to prevent HIV-1 transmission by breastfeeding: the PROMISE-PEP trial Protocol ANRS 12174.
Nagot N; Kankasa C; Meda N; Hofmeyr J; Nikodem C; Tumwine JK; Karamagi C; Sommerfelt H; Neveu D; Tylleskär T; Van de Perre P;
BMC Infect Dis; 2012 Oct; 12():246. PubMed ID: 23039034
[TBL] [Abstract][Full Text] [Related]
31. A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers.
Gray GE; Urban M; Chersich MF; Bolton C; van Niekerk R; Violari A; Stevens W; McIntyre JA;
AIDS; 2005 Aug; 19(12):1289-97. PubMed ID: 16052084
[TBL] [Abstract][Full Text] [Related]
32. Integration of postpartum healthcare services for HIV-infected women and their infants in South Africa: A randomised controlled trial.
Myer L; Phillips TK; Zerbe A; Brittain K; Lesosky M; Hsiao NY; Remien RH; Mellins CA; McIntyre JA; Abrams EJ
PLoS Med; 2018 Mar; 15(3):e1002547. PubMed ID: 29601570
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial.
Petra Study Team
Lancet; 2002 Apr; 359(9313):1178-86. PubMed ID: 11955535
[TBL] [Abstract][Full Text] [Related]
34. Integrated prevention of mother-to-child HIV transmission services, antiretroviral therapy initiation, and maternal and infant retention in care in rural north-central Nigeria: a cluster-randomised controlled trial.
Aliyu MH; Blevins M; Audet CM; Kalish M; Gebi UI; Onwujekwe O; Lindegren ML; Shepherd BE; Wester CW; Vermund SH
Lancet HIV; 2016 May; 3(5):e202-11. PubMed ID: 27126487
[TBL] [Abstract][Full Text] [Related]
35. Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study.
Kilewo C; Karlsson K; Ngarina M; Massawe A; Lyamuya E; Swai A; Lipyoga R; Mhalu F; Biberfeld G;
J Acquir Immune Defic Syndr; 2009 Nov; 52(3):406-16. PubMed ID: 19730269
[TBL] [Abstract][Full Text] [Related]
36. Maternal Highly Active Antiretroviral Therapy and Child HIV-Free Survival in Malawi, 2004-2009.
Schwartz SR; Kumwenda N; Kumwenda J; Chen S; Mofenson LM; Taylor AW; Fowler MG; Taha TE
Matern Child Health J; 2016 Mar; 20(3):542-9. PubMed ID: 26525557
[TBL] [Abstract][Full Text] [Related]
37. Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV.
Palombi L; Marazzi MC; Voetberg A; Magid NA
AIDS; 2007 Jul; 21 Suppl 4():S65-71. PubMed ID: 17620755
[TBL] [Abstract][Full Text] [Related]
38. Maternal HIV-1 disease progression 18-24 months postdelivery according to antiretroviral prophylaxis regimen (triple-antiretroviral prophylaxis during pregnancy and breastfeeding vs zidovudine/single-dose nevirapine prophylaxis): The Kesho Bora randomized controlled trial.
Kesho Bora Study Group
Clin Infect Dis; 2012 Aug; 55(3):449-60. PubMed ID: 22573845
[TBL] [Abstract][Full Text] [Related]
39. Antiretroviral treatment for children with peripartum nevirapine exposure.
Palumbo P; Lindsey JC; Hughes MD; Cotton MF; Bobat R; Meyers T; Bwakura-Dangarembizi M; Chi BH; Musoke P; Kamthunzi P; Schimana W; Purdue L; Eshleman SH; Abrams EJ; Millar L; Petzold E; Mofenson LM; Jean-Philippe P; Violari A
N Engl J Med; 2010 Oct; 363(16):1510-20. PubMed ID: 20942667
[TBL] [Abstract][Full Text] [Related]
40. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis.
Zeh C; Weidle PJ; Nafisa L; Lwamba HM; Okonji J; Anyango E; Bondo P; Masaba R; Fowler MG; Nkengasong JN; Thigpen MC; Thomas T
PLoS Med; 2011 Mar; 8(3):e1000430. PubMed ID: 21468304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
